{"id":"https://openalex.org/W2365407196","doi":"https://doi.org/10.1158/1535-7163.targ-15-c49","title":"Abstract C49: Phase 1 study of CB-839, a first-in-class, orally administered small molecule inhibitor of glutaminase in patients with refractory solid tumors","display_name":"Abstract C49: Phase 1 study of CB-839, a first-in-class, orally administered small molecule inhibitor of glutaminase in patients with refractory solid tumors","publication_year":2015,"publication_date":"2015-12-01","ids":{"openalex":"https://openalex.org/W2365407196","doi":"https://doi.org/10.1158/1535-7163.targ-15-c49","mag":"2365407196"},"language":"en","primary_location":{"id":"doi:10.1158/1535-7163.targ-15-c49","doi":"https://doi.org/10.1158/1535-7163.targ-15-c49","is_oa":false,"landing_page_url":"https://doi.org/10.1158/1535-7163.targ-15-c49","pdf_url":null,"source":{"id":"https://openalex.org/S48437117","display_name":"Molecular Cancer Therapeutics","issn_l":"1535-7163","issn":["1535-7163","1538-8514"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Molecular Cancer Therapeutics","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","is_traditional":false,"indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5076426660","display_name":"Funda Meric\u2010Bernstam","orcid":"https://orcid.org/0000-0001-6816-6072","observed_orcids":["https://orcid.org/0000-0001-6816-6072"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Funda Meric-Bernstam","raw_affiliation_strings":["1MD Anderson Cancer Center, Houston, TX;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1MD Anderson Cancer Center, Houston, TX;","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5005537242","display_name":"Angela M. DeMichele","orcid":"https://orcid.org/0000-0003-1297-4251","observed_orcids":["https://orcid.org/0000-0003-1297-4251"]},"institutions":[{"id":"https://openalex.org/I79576946","display_name":"University of Pennsylvania","ror":"https://ror.org/00b30xv10","country_code":"US","type":"education","lineage":["https://openalex.org/I79576946"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Angela DeMichele","raw_affiliation_strings":["2University of Pennsylvania, Philadelphia, PA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"2University of Pennsylvania, Philadelphia, PA;","institution_ids":["https://openalex.org/I79576946"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5052487618","display_name":"Melinda L. Telli","orcid":"https://orcid.org/0000-0001-7993-1235","observed_orcids":["https://orcid.org/0000-0001-7993-1235"]},"institutions":[{"id":"https://openalex.org/I97018004","display_name":"Stanford University","ror":"https://ror.org/00f54p054","country_code":"US","type":"education","lineage":["https://openalex.org/I97018004"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Melinda L. Telli","raw_affiliation_strings":["3Stanford University, Stanford, CA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"3Stanford University, Stanford, CA;","institution_ids":["https://openalex.org/I97018004"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5083373965","display_name":"Pamela N. M\u00fcnster","orcid":"https://orcid.org/0000-0002-2074-0984","observed_orcids":["https://orcid.org/0000-0002-2074-0984","https://orcid.org/0009-0009-4141-2312"]},"institutions":[{"id":"https://openalex.org/I180670191","display_name":"University of California, San Francisco","ror":"https://ror.org/043mz5j54","country_code":"US","type":"education","lineage":["https://openalex.org/I180670191"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Pamela Munster","raw_affiliation_strings":["4University of California, San Franscisco, San Francisco, CA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"4University of California, San Franscisco, San Francisco, CA;","institution_ids":["https://openalex.org/I180670191"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5109262452","display_name":"Keith William Orford","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210115323","display_name":"Calithera (United States)","ror":"https://ror.org/029gt5q28","country_code":"US","type":"company","lineage":["https://openalex.org/I4210115323"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Keith W. Orford","raw_affiliation_strings":["5Calithera Biosciences, Inc., South San Francisco, CA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"5Calithera Biosciences, Inc., South San Francisco, CA;","institution_ids":["https://openalex.org/I4210115323"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5077055792","display_name":"George D. Demitri","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"George D. Demitri","raw_affiliation_strings":["6Dana-Farber Cancer Institute, Boston, MA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"6Dana-Farber Cancer Institute, Boston, MA;","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5006913373","display_name":"Gary K. Schwartz","orcid":"https://orcid.org/0000-0003-1813-5061","observed_orcids":["https://orcid.org/0000-0003-1813-5061"]},"institutions":[{"id":"https://openalex.org/I2799503643","display_name":"Columbia University Irving Medical Center","ror":"https://ror.org/01esghr10","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I2799503643"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Gary K. Schwartz","raw_affiliation_strings":["7Columbia University Medical Center, New York, NY;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"7Columbia University Medical Center, New York, NY;","institution_ids":["https://openalex.org/I2799503643"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5038992904","display_name":"Othon Iliopoulos","orcid":"https://orcid.org/0000-0002-4444-6157","observed_orcids":["https://orcid.org/0000-0002-4444-6157"]},"institutions":[{"id":"https://openalex.org/I4210087915","display_name":"Massachusetts General Hospital","ror":"https://ror.org/002pd6e78","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210087915","https://openalex.org/I48633490"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Othon Iliopoulos","raw_affiliation_strings":["8Massachusetts General Hospital, Boston, MA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"8Massachusetts General Hospital, Boston, MA;","institution_ids":["https://openalex.org/I4210087915"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5108518835","display_name":"James Walter Mier","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1316535847","display_name":"Beth Israel Deaconess Medical Center","ror":"https://ror.org/04drvxt59","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1316535847"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"James W. Mier","raw_affiliation_strings":["9Beth Isreal Deaconess Medical Center, Boston, MA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"9Beth Isreal Deaconess Medical Center, Boston, MA;","institution_ids":["https://openalex.org/I1316535847"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5015060656","display_name":"Taofeek Kunle Owonikoko","orcid":"https://orcid.org/0000-0002-7724-7728","observed_orcids":["https://orcid.org/0000-0002-7724-7728"]},"institutions":[{"id":"https://openalex.org/I150468666","display_name":"Emory University","ror":"https://ror.org/03czfpz43","country_code":"US","type":"education","lineage":["https://openalex.org/I150468666"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Taofeek K. Owonikoko","raw_affiliation_strings":["10Emory University, Atlanta, GA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"10Emory University, Atlanta, GA;","institution_ids":["https://openalex.org/I150468666"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5055304416","display_name":"Mark K. Bennett","orcid":"https://orcid.org/0000-0003-1046-1292","observed_orcids":["https://orcid.org/0000-0003-1046-1292"]},"institutions":[{"id":"https://openalex.org/I4210115323","display_name":"Calithera (United States)","ror":"https://ror.org/029gt5q28","country_code":"US","type":"company","lineage":["https://openalex.org/I4210115323"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Mark K. Bennett","raw_affiliation_strings":["5Calithera Biosciences, Inc., South San Francisco, CA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"5Calithera Biosciences, Inc., South San Francisco, CA;","institution_ids":["https://openalex.org/I4210115323"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5005718112","display_name":"Manish R. Patel","orcid":"https://orcid.org/0000-0001-6836-2364","observed_orcids":["https://orcid.org/0000-0001-6836-2364"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Manish R. Patel","raw_affiliation_strings":["11Florida Cancer Specialists, Sarasota, FL;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"11Florida Cancer Specialists, Sarasota, FL;","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5034983144","display_name":"Jeffery R. Infante","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210100810","display_name":"Sarah Cannon","ror":"https://ror.org/014t21j89","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210100810"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jeffery R. Infante","raw_affiliation_strings":["12Sarah Cannon Research Institute, Nashville, TN;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"12Sarah Cannon Research Institute, Nashville, TN;","institution_ids":["https://openalex.org/I4210100810"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5065435809","display_name":"James J. Harding","orcid":"https://orcid.org/0000-0002-7029-4310","observed_orcids":["https://orcid.org/0000-0002-7029-4310","https://orcid.org/0000-0003-0766-9965"]},"institutions":[{"id":"https://openalex.org/I1334819555","display_name":"Memorial Sloan Kettering Cancer Center","ror":"https://ror.org/02yrq0923","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1334819555"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"James J. Harding","raw_affiliation_strings":["13Memorial Sloan Kettering Cancer Center, New York, NY"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"13Memorial Sloan Kettering Cancer Center, New York, NY","institution_ids":["https://openalex.org/I1334819555"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":12,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":8,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"14","issue":"12_Supplement_2","first_page":"C49","last_page":"C49"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10631","display_name":"Cancer, Hypoxia, and Metabolism","score":0.7455999851226807,"subfield":{"id":"https://openalex.org/subfields/1306","display_name":"Cancer Research"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T10631","display_name":"Cancer, Hypoxia, and Metabolism","score":0.7455999851226807,"subfield":{"id":"https://openalex.org/subfields/1306","display_name":"Cancer Research"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T12770","display_name":"Amino Acid Enzymes and Metabolism","score":0.20509999990463257,"subfield":{"id":"https://openalex.org/subfields/1303","display_name":"Biochemistry"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T12996","display_name":"Bacterial Cancer Therapy","score":0.005799999926239252,"subfield":{"id":"https://openalex.org/subfields/1305","display_name":"Biotechnology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/cb-839","display_name":"CB-839","score":0.996999979019165},{"id":"https://openalex.org/keywords/glutaminase-inhibitors","display_name":"glutaminase inhibitors","score":0.9079999923706055},{"id":"https://openalex.org/keywords/refractory-solid-tumors","display_name":"refractory solid tumors","score":0.8479999899864197},{"id":"https://openalex.org/keywords/triple-negative-breast-cancer","display_name":"triple-negative breast cancer","score":0.8100000023841858},{"id":"https://openalex.org/keywords/kras-mutant-non-small-cell-lung-cancer","display_name":"KRAS-mutant non-small cell lung cancer","score":0.9869999885559082},{"id":"https://openalex.org/keywords/clear-cell-renal-cell-carcinoma","display_name":"clear cell renal cell carcinoma","score":0.9660000205039978},{"id":"https://openalex.org/keywords/mesothelioma","display_name":"mesothelioma","score":0.996999979019165},{"id":"https://openalex.org/keywords/pharmacokinetics","display_name":"pharmacokinetics","score":0.7860000133514404},{"id":"https://openalex.org/keywords/pharmacodynamics","display_name":"pharmacodynamics","score":0.8809999823570251},{"id":"https://openalex.org/keywords/platelet-count","display_name":"platelet count","score":0.39100000262260437},{"id":"https://openalex.org/keywords/recommended-phase-ii-dose","display_name":"recommended phase 2 dose","score":0.7110000252723694},{"id":"https://openalex.org/keywords/dose-limiting-toxicity","display_name":"dose-limiting toxicity","score":0.8119999766349792},{"id":"https://openalex.org/keywords/drug-safety-and-tolerability","display_name":"drug safety and tolerability","score":0.6269999742507935},{"id":"https://openalex.org/keywords/combination-chemotherapy","display_name":"combination chemotherapy","score":0.5619999766349792},{"id":"https://openalex.org/keywords/paclitaxel","display_name":"paclitaxel","score":0.8019999861717224}],"concepts":[{"id":"https://openalex.org/C2781187634","wikidata":"https://www.wikidata.org/wiki/Q20969980","display_name":"KRAS","level":4,"score":0.7270467877388},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.6962605118751526},{"id":"https://openalex.org/C2778375690","wikidata":"https://www.wikidata.org/wiki/Q7814214","display_name":"Tolerability","level":3,"score":0.6149131059646606},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.49260979890823364},{"id":"https://openalex.org/C109549099","wikidata":"https://www.wikidata.org/wiki/Q24773687","display_name":"Glutaminase","level":4,"score":0.4905776083469391},{"id":"https://openalex.org/C111113717","wikidata":"https://www.wikidata.org/wiki/Q725307","display_name":"Pharmacodynamics","level":3,"score":0.4641460180282593},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.4504035413265228},{"id":"https://openalex.org/C2778087573","wikidata":"https://www.wikidata.org/wiki/Q418369","display_name":"Erlotinib","level":4,"score":0.4467747211456299},{"id":"https://openalex.org/C2776256026","wikidata":"https://www.wikidata.org/wiki/Q47912","display_name":"Lung cancer","level":2,"score":0.4345915913581848},{"id":"https://openalex.org/C2781190966","wikidata":"https://www.wikidata.org/wiki/Q420436","display_name":"Docetaxel","level":3,"score":0.4198298454284668},{"id":"https://openalex.org/C112705442","wikidata":"https://www.wikidata.org/wiki/Q323936","display_name":"Pharmacokinetics","level":2,"score":0.4109686613082886},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.4070362150669098},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.3853365182876587},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.3456975817680359},{"id":"https://openalex.org/C526805850","wikidata":"https://www.wikidata.org/wiki/Q188874","display_name":"Colorectal cancer","level":3,"score":0.19924300909042358},{"id":"https://openalex.org/C2779438470","wikidata":"https://www.wikidata.org/wiki/Q424401","display_name":"Epidermal growth factor receptor","level":3,"score":0.18147915601730347},{"id":"https://openalex.org/C61174792","wikidata":"https://www.wikidata.org/wiki/Q420510","display_name":"Glutamate receptor","level":3,"score":0.0},{"id":"https://openalex.org/C170493617","wikidata":"https://www.wikidata.org/wiki/Q208467","display_name":"Receptor","level":2,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1158/1535-7163.targ-15-c49","doi":"https://doi.org/10.1158/1535-7163.targ-15-c49","is_oa":false,"landing_page_url":"https://doi.org/10.1158/1535-7163.targ-15-c49","pdf_url":null,"source":{"id":"https://openalex.org/S48437117","display_name":"Molecular Cancer Therapeutics","issn_l":"1535-7163","issn":["1535-7163","1538-8514"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Molecular Cancer Therapeutics","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","score":0.9537000060081482,"id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2601158320","https://openalex.org/W2730941312","https://openalex.org/W2793698321","https://openalex.org/W2929070425","https://openalex.org/W1908982398","https://openalex.org/W2132117833","https://openalex.org/W1971369673","https://openalex.org/W2095003652","https://openalex.org/W2226965945","https://openalex.org/W2564887186"],"abstract_inverted_index":{"Abstract":[0],"Background:":[1],"CB-839":[2,45,80,111,208,391,496,554],"is":[3,101,159,170,178],"a":[4,12,37,241,253,264,270,415,464,547,560,614],"first-in-class":[5],"highly":[6],"selective":[7],"inhibitor":[8,620],"of":[9,18,25,30,39,91,107,110,244,250,315,327,343,353,357,386,399,417,424,431,445,514,522,553,612,621,632],"glutaminase":[10,622],"(GLS),":[11],"key":[13],"enzyme":[14],"in":[15,55,114,118,180,183,209,216,219,223,228,237,269,286,294,317,383,467,483,516,519,525,536,555,564,623],"the":[16,28,134,157,192,198,238,276,291,309,324,339,350,354,393,404,438,633],"utilization":[17],"glutamine":[19,35],"by":[20,474],"many":[21],"cancer":[22,59,65,71],"cells.":[23],"Inhibition":[24],"GLS":[26,77,316,470,515],"blocks":[27],"ability":[29],"tumor":[31,123,184,199,468,486,557],"cells":[32],"to":[33,85,126,132,257,478,481],"use":[34],"as":[36,203,205,356,559],"source":[38],"energy":[40],"and":[41,73,95,129,131,154,175,182,226,369,396,461,476,507,518,544,563,639],"anabolic":[42],"building":[43],"blocks.":[44],"has":[46,81,453,462,497],"broad":[47],"activity,":[48],"inducing":[49],"cell":[50,63,68,70,75],"death":[51],"or":[52],"growth":[53],"arrest":[54],"triple":[56],"negative":[57],"breast":[58],"(TNBC),":[60],"KRAS-mutant":[61,220],"non-small":[62],"lung":[64],"(NSCLC),":[66],"clear":[67,548],"renal":[69],"(RCC),":[72],"mesothelioma":[74],"lines.":[76],"inhibition":[78,314,331,513],"with":[79,88,166,197,211,247,272,298,329,408,504,532,538,566,625],"also":[82,492],"been":[83,347,411,498],"shown":[84],"synergistically":[86],"combine":[87],"several":[89,556],"standard":[90],"care":[92],"(SOC)":[93],"chemotherapies":[94],"signal":[96],"transduction":[97],"inhibitors.":[98],"Methods:":[99],"CX-839-001":[100],"an":[102],"ongoing":[103],"Phase":[104,136,609],"1":[105,174,610],"study":[106,413,611],"escalating":[108],"doses":[109,509],"given":[112,143,162],"continuously":[113],"21":[115],"day":[116],"cycles":[117,419],"advanced":[119],"and/or":[120],"treatment-refractory":[121],"solid":[122,627],"patients":[124,624],"(pts)":[125],"evaluate":[127],"safety":[128,155],"tolerability,":[130],"identify":[133],"recommended":[135],"2":[137],"dose":[138,280,326,440],"(R2PD).":[139],"It":[140],"was":[141,319,381,472],"initially":[142],"three":[144],"times":[145],"daily":[146,164],"(TID)":[147],"without":[148],"food,":[149],"but":[150],"based":[151],"on":[152,172,262,290,349,364,372,392,403,412,428,437,448],"PK":[153,333],"data,":[156],"drug":[158],"now":[160],"being":[161,189],"twice":[163],"(BID)":[165],"meals.":[167],"Pharmacokinetics":[168],"(PK)":[169],"monitored":[171],"Days":[173],"15;":[176],"pharmacodynamics":[177],"measured":[179],"platelets":[181,318,517],"biopsies.":[185],"Pts":[186,407],"are":[187],"currently":[188],"enrolled":[190,236,348],"at":[191,275,332,338,506],"RP2D,":[193],"600":[194],"mg":[195,278],"BID,":[196],"types":[200],"noted":[201],"above":[202,508],"well":[204,499],"pts":[206,235,251,296,306,337,345,363,371,389,402,426,436,526],"receiving":[207,308,390,527],"combination":[210,537,565],"SOC":[212,539,567],"agents,":[213],"including":[214,361,541],"paclitaxel":[215],"TNBC,":[217],"docetaxel":[218],"NSCLC,":[221,225],"erlotinib":[222],"EGFR-mutant":[224],"everolimus":[227,543],"RCC.":[229],"Results:":[230],"Safety":[231],"data":[232,535],"from":[233],"85":[234],"trial":[239,355],"revealed":[240],"low":[242],"rate":[243],"Gr3/4":[245,254],"AEs,":[246],"9.4%":[248],"(8/85)":[249],"experiencing":[252],"AE":[255],"related":[256],"CB-839.":[258],"One":[259],"DLT":[260],"occurred":[261,288],"study,":[263],"drug-related":[265],"Gr3":[266,284,301],"creatinine":[267],"elevation":[268],"patient":[271,452,485],"diabetic":[273],"nephropathy":[274],"250":[277],"TID":[279,292,365,394],"level.":[281],"Reversible,":[282],"asymptomatic":[283],"elevations":[285],"transaminases":[287],"mostly":[289],"schedule":[293,395,441],"6/32":[295],"(18.8%),":[297],"only":[299],"one":[300,459],"event":[302],"occurring":[303],"among":[304],"53":[305],"(1.9%)":[307],"BID":[310,373,405,439,503],"regimen.":[311],"Clear":[312],"exposure-dependent":[313],"seen":[320],"4":[321],"hr":[322],"after":[323],"first":[325],"CB-839,":[328,530,613],">90%":[330],"trough":[334],"for":[335,414,456,550],"most":[336,484],"RP2D.":[340],"A":[341,450],"total":[342],"93":[344],"have":[346,410],"monotherapy":[351],"cohorts":[352],"24":[358],"July":[359],"2015,":[360],"32":[362],"dosing":[366,374],"(100-800":[367],"mg)":[368],"61":[370],"(600-1000":[375],"mg).":[376],"Radiographic":[377],"stable":[378],"disease":[379],"(SD)":[380],"observed":[382],"6":[384],"(19%)":[385],"31":[387],"efficacy-evaluable":[388,401],"17":[397],"(40%)":[398],"43":[400],"schedule.":[406],"SD":[409,455,524],"median":[416],">5":[418],"(range":[420],"3-18);":[421],"15":[422],"(65%)":[423],"these":[425],"remain":[427,447],"treatment.":[429],"Seven":[430],"11":[432],"(64%)":[433],"evaluable":[434],"RCC":[435],"showed":[442],"SD,":[443],"5":[444],"whom":[446],"study.":[449],"TNBC":[451],"maintained":[454],"more":[457],"than":[458],"year":[460],"had":[463],"23%":[465],"reduction":[466],"burden.":[469],"expression":[471],"evaluated":[473],"IHC":[475],"found":[477],"be":[479,493],"moderate":[480],"high":[482],"samples.":[487],"Additional":[488],"correlative":[489],"studies":[490],"will":[491],"presented.":[494],"Conclusions:":[495],"tolerated":[500],"when":[501],"administered":[502,617],"food":[505],"that":[510],"produced":[511],"robust":[512],"tumors.":[520,628],"Evidence":[521],"prolonged":[523],"single":[528,561],"agent":[529,562],"together":[531],"strong":[533],"preclinical":[534],"agents":[540],"paclitaxel,":[542],"erlotinib,":[545],"provides":[546],"rationale":[549],"continued":[551],"evaluation":[552],"types,":[558],"therapies.":[568],"Citation":[569],"Format:":[570],"Funda":[571],"Meric-Bernstam,":[572],"Angela":[573],"DeMichele,":[574],"Melinda":[575],"L.":[576],"Telli,":[577],"Pamela":[578],"Munster,":[579],"Keith":[580],"W.":[581,592],"Orford,":[582],"George":[583],"D.":[584],"Demitri,":[585],"Gary":[586],"K.":[587,595,598],"Schwartz,":[588],"Othon":[589],"Iliopoulos,":[590],"James":[591,606],"Mier,":[593],"Taofeek":[594],"Owonikoko,":[596],"Mark":[597],"Bennett,":[599],"Manish":[600],"R.":[601,604],"Patel,":[602],"Jeffery":[603],"Infante,":[605],"J.":[607],"Harding.":[608],"first-in-class,":[615],"orally":[616],"small":[618],"molecule":[619],"refractory":[626],"[abstract].":[629],"In:":[630],"Proceedings":[631],"AACR-NCI-EORTC":[634],"International":[635],"Conference:":[636],"Molecular":[637],"Targets":[638],"Cancer":[640,651],"Therapeutics;":[641],"2015":[642],"Nov":[643],"5-9;":[644],"Boston,":[645],"MA.":[646],"Philadelphia":[647],"(PA):":[648],"AACR;":[649],"Mol":[650],"Ther":[652],"2015;14(12":[653],"Suppl":[654],"2):Abstract":[655],"nr":[656],"C49.":[657]},"counts_by_year":[{"year":2025,"cited_by_count":2},{"year":2022,"cited_by_count":2},{"year":2020,"cited_by_count":1},{"year":2019,"cited_by_count":2},{"year":2018,"cited_by_count":1}],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2016-06-24T00:00:00"}